Featured Articles

31. Artful Taste Masking Improves Patient Compliance 5/12/2022

    Taste masking is required for dosage forms that interact with the taste buds. Discover some of the best and most practical taste masking methods to consider for each API.

32. Meet The Scientist — Bryan Braxton, Ph.D. 2/5/2021

    Bryan Braxton has a friendly, grounded demeanor and a scientific mind that creates solutions for our most complex aseptic development projects. But how did these two traits combine in the same person?

33. Preventing Cross-Contamination – Operating Beyond cGMP

    One critical outcome universally accepted by the pharmaceutical industry is that cross-contamination of drug substances and products in manufacturing lines cannot occur. However, the conditions driving modern pharmaceutical development and manufacturing have increased the risk of cross-contamination.

34. Meet Barbara Holland, Business Development Director 5/12/2022

    Barbara Holland, Business Development Director at Pii, is a bit of a renaissance woman. Learn about her personal interests and why she came out of retirement to work with customers.

35. Applying The Four Dimensions Of Sustainability To Create Capacity That Delivers Results Faster

    There are no shortcuts to growing capacity that delivers results faster and maintaining it is difficult. The key ingredient in growing enterprise value is sustainability. Learn how by applying the principle of sustainability using its four dimensions, finite resources are more wisely used with extraordinary results, lead time from concept to commercialization is greatly improved, and patients receive better medications faster.

36. Scaling Aseptic Pharmaceutical Production During Uncertainty

    Aseptic production and fill/finish operations are complex, and unexpected challenges should not disrupt the outcome of delivering needed pharmaceutical products to patients.

37. Demystifying Highly Potent API And Cytotoxic Drug Products

    The concept of development, process design, and manufacturing of drugs with a HPAPI or cytotoxic compounds should not be a mystery to drug sponsors using a CDMO. Gathering, organizing, and understanding critical risk data related to HPAPIs and cytotoxic drugs ensures appropriate controls are defined from concept to clinical batch manufacturing to commercial-scale manufacturing.

38. Meet The Scientist — Irina Prudnikova

    Analytical research and development (R&D) works in close collaboration with formulation and process R&D to support the overall development process. Irina’s team is often the catalyst for transforming a development candidate into a viable drug formulation that improves patients' lives.

39. Oxygen Sensitive Drug Products

    Primary packaging is thought of as the first line of defense against the negative effects of oxygen. This article highlights other areas to consider that can help avoid drug quality degradation.

40. The Art And Science Of Tech Transfer – Transferring Vaccine Production

    Facilities committed to prioritizing COVID-19 production are forcing non-COVID-19 vaccine makers to shift their production needs to other facilities, requiring a technology transfer in each case.